Adham Mustapha, Jaeck Daniel, Le Borgne Joël, Oussoultzouglou Elie, Chenard-Neu Marie-Pierre, Mosnier Jean-François, Scoazec Jean-Yves, Mornex Françoise, Partensky Christian
Department of Hepato-Bilio-Pancreatic Surgery and Transplantation, Lyon University Hospital, Lyon, France.
Pancreas. 2008 Nov;37(4):352-7. doi: 10.1097/MPA.0b013e31818166d2.
Long-term survival after pancreatectomy for pancreatic duct adenocarcinoma has been rarely reported. Factors influencing survival are still debated. The aim of the study is to report a French multicentric series of long-term survivors after pancreatectomy for pancreatic duct adenocarcinoma.
Data of patients who survived >5 years (February 1983-January 2000) were analyzed. All operative specimens were reviewed. Patients with intraductal-papillary-mucinous-neoplasia, cystadenocarcinoma, acinous-adenocarcinoma, neuroendocrine, or mixed tumors were excluded.
Long-term survivors were 20 men and 10 women, with median age of 61 years. Twenty-five patients had pancreaticoduodenectomies (6 pylorus preserving pancreatoduodenectomy [PPPD]), 3 had total pancreaticoduodenectomies, and 2 had splenopancreatectomies. Three patients had portal vein resection, 1 had hepatic artery resection-reconstruction, and 1 had segmentectomy for liver metastasis. All resections were complete macroscopic and microscopic resection (R0). Median tumor size was 30 mm. Tumors were pT2 (n = 1), pT3 (n = 24), pT4 (n = 5), 12 N+, 1 M+. Twenty patients had adjuvant radiotherapy, and 18 had concomitant chemotherapy. Median survival was 7.3 years (range, 5.2-21 years). Nineteen patients are alive, 1 with recurrence and 18 with no evidence of disease (2 had more than 20 years of follow-up). Eleven patients died, 6 from recurrence.
Pancreatic duct adenocarcinoma can be cured, and long-term survival after R0 curative surgery has become a reality. Long-term survivors did not fulfil the ideal prognostic criteria and even presented with advanced stage.
关于胰腺导管腺癌胰腺切除术后长期生存的报道极少。影响生存的因素仍存在争议。本研究旨在报告一组法国多中心胰腺导管腺癌胰腺切除术后长期存活者。
分析存活时间超过5年(1983年2月至2000年1月)患者的数据。所有手术标本均进行复查。排除导管内乳头状黏液性肿瘤、囊腺癌、腺泡腺癌、神经内分泌肿瘤或混合性肿瘤患者。
长期存活者中男性20例,女性10例,中位年龄61岁。25例行胰十二指肠切除术(6例保留幽门的胰十二指肠切除术[PPPD]),3例行全胰十二指肠切除术,2例行脾胰切除术。3例患者行门静脉切除,1例行肝动脉切除重建,1例行肝转移瘤段切除术。所有切除均为肉眼及显微镜下完整切除(R0)。肿瘤中位大小为30 mm。肿瘤分期为pT2(n = 1)、pT3(n = 24)、pT4(n = 5),12例N+,1例M+。20例患者接受辅助放疗,18例接受同步化疗。中位生存期为7.3年(范围5.2 - 21年)。19例患者存活,1例复发,18例无疾病证据(2例随访超过20年)。11例患者死亡,6例死于复发。
胰腺导管腺癌可以治愈,R0根治性手术后长期生存已成为现实。长期存活者未达到理想的预后标准,甚至呈现晚期。